JP2016509586A5 - - Google Patents

Info

Publication number

JP2016509586A5

JP2016509586A5 JP2015550080A JP2015550080A JP2016509586A5 JP 2016509586 A5 JP2016509586 A5 JP 2016509586A5 JP 2015550080 A JP2015550080 A JP 2015550080A JP 2015550080 A JP2015550080 A JP 2015550080A JP 2016509586 A5 JP2016509586 A5 JP 2016509586A5

Authority

JP

Japan

Prior art keywords

drug

compound

group

linker

seq

Prior art date

2013-12-27

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003814 drug Substances 0.000 claims description 86
• 229940079593 drug Drugs 0.000 claims description 85
• 150000001875 compounds Chemical class 0.000 claims description 51
• 150000003839 salts Chemical class 0.000 claims description 26
• 238000000034 method Methods 0.000 claims description 25
• 206010028980 Neoplasm Diseases 0.000 claims description 18
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
• 239000000203 mixture Substances 0.000 claims description 14
• 201000011510 cancer Diseases 0.000 claims description 13
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 12
• VLZMFVRHOYPDFA-UHFFFAOYSA-N 12-(morpholin-4-ylmethyl)-3,10,11-triazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13),11-pentaen-9-one Chemical compound O=C1NN=C(CN2CCOCC2)C2=CNC3=CC=CC1=C23 VLZMFVRHOYPDFA-UHFFFAOYSA-N 0.000 claims description 11
• 108010038807 Oligopeptides Proteins 0.000 claims description 10
• 102000015636 Oligopeptides Human genes 0.000 claims description 10
• 239000003795 chemical substances by application Substances 0.000 claims description 10
• 101100226491 Homo sapiens FAM83A gene Proteins 0.000 claims description 9
• 102100035446 Protein FAM83A Human genes 0.000 claims description 9
• 108010016626 Dipeptides Proteins 0.000 claims description 7
• 229960004679 doxorubicin Drugs 0.000 claims description 7
• 238000012216 screening Methods 0.000 claims description 7
• 102000035195 Peptidases Human genes 0.000 claims description 6
• 108091005804 Peptidases Proteins 0.000 claims description 6
• 238000006243 chemical reaction Methods 0.000 claims description 6
• 210000004748 cultured cell Anatomy 0.000 claims description 6
• 238000000338 in vitro Methods 0.000 claims description 6
• 235000019833 protease Nutrition 0.000 claims description 6
• -1 phosphonoacetyl group Chemical group 0.000 claims description 5
• 206010059866 Drug resistance Diseases 0.000 claims description 4
• 239000002246 antineoplastic agent Substances 0.000 claims description 4
• 229940041181 antineoplastic drug Drugs 0.000 claims description 4
• 238000002512 chemotherapy Methods 0.000 claims description 4
• 238000009096 combination chemotherapy Methods 0.000 claims description 4
• 230000001472 cytotoxic effect Effects 0.000 claims description 4
• 230000003013 cytotoxicity Effects 0.000 claims description 4
• 231100000135 cytotoxicity Toxicity 0.000 claims description 4
• 238000003379 elimination reaction Methods 0.000 claims description 3
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 claims description 2
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 2
• 206010048610 Cardiotoxicity Diseases 0.000 claims description 2
• JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 claims description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
• 229930126263 Maytansine Natural products 0.000 claims description 2
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
• 102000003729 Neprilysin Human genes 0.000 claims description 2
• 108090000028 Neprilysin Proteins 0.000 claims description 2
• 229930012538 Paclitaxel Natural products 0.000 claims description 2
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
• 229960003896 aminopterin Drugs 0.000 claims description 2
• 229960002550 amrubicin Drugs 0.000 claims description 2
• VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 claims description 2
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 2
• 229940127093 camptothecin Drugs 0.000 claims description 2
• 231100000259 cardiotoxicity Toxicity 0.000 claims description 2
• 239000003085 diluting agent Substances 0.000 claims description 2
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 2
• 229960003668 docetaxel Drugs 0.000 claims description 2
• 239000012634 fragment Substances 0.000 claims description 2
• QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 claims description 2
• 201000002364 leukopenia Diseases 0.000 claims description 2
• 231100001022 leukopenia Toxicity 0.000 claims description 2
• WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 claims description 2
• 229960000485 methotrexate Drugs 0.000 claims description 2
• 229960001592 paclitaxel Drugs 0.000 claims description 2
• 239000002904 solvent Substances 0.000 claims description 2
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
• 229960003048 vinblastine Drugs 0.000 claims description 2
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
• 229960004528 vincristine Drugs 0.000 claims description 2
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
• 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims 2
• 238000002360 preparation method Methods 0.000 claims 1
• 229940002612 prodrug Drugs 0.000 description 51
• 239000000651 prodrug Substances 0.000 description 51
• 102000004196 processed proteins & peptides Human genes 0.000 description 15
• MHJJUOJOAJLYBS-ZBRNBAAYSA-N (2s)-2-aminopropanoic acid;(2s)-pyrrolidine-2-carboxylic acid Chemical compound C[C@H](N)C(O)=O.OC(=O)[C@@H]1CCCN1 MHJJUOJOAJLYBS-ZBRNBAAYSA-N 0.000 description 10
• KZNQNBZMBZJQJO-UHFFFAOYSA-N 1-(2-azaniumylacetyl)pyrrolidine-2-carboxylate Chemical compound NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 10
• 150000001413 amino acids Chemical class 0.000 description 10
• 210000000440 neutrophil Anatomy 0.000 description 3
• KQRHTCDQWJLLME-XUXIUFHCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N KQRHTCDQWJLLME-XUXIUFHCSA-N 0.000 description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
• RUQBGIMJQUWXPP-CYDGBPFRSA-N Ala-Leu-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O RUQBGIMJQUWXPP-CYDGBPFRSA-N 0.000 description 2
• AIXUQKMMBQJZCU-IUCAKERBSA-N Lys-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O AIXUQKMMBQJZCU-IUCAKERBSA-N 0.000 description 2
• 108010054982 alanyl-leucyl-alanyl-leucine Proteins 0.000 description 2
• 230000001268 conjugating effect Effects 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• 108010066082 tartrate-sensitive acid phosphatase Proteins 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 230000000694 effects Effects 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 208000004235 neutropenia Diseases 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1